| Identification | Back Directory | [Name]
Secukinumab | [CAS]
1229022-83-6 | [Synonyms]
AIN457
AIN-457
AIN 457
Secukinumab
Secukinumab (anti-IL-17A)
Research Grade Secukinumab(DHH28802) | [MDL Number]
MFCD01092388 |
| Hazard Information | Back Directory | [Uses]
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2]. | [Clinical Use]
Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis,
psoriatic arthritis, ankylosing spondylitis | [Drug interactions]
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | [IC 50]
IL-17A | [Metabolism]
The majority of IgG elimination occurs via intracellular
catabolism, following fluid-phase or receptor mediated
endocytosis. | [References]
[1] Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76(11):1135-1145. DOI:10.1007/s40265-016-0602-3
[2] Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304-315. DOI:10.1007/s40265-016-0602-3
[3] Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62(5):725-735. DOI:10.1002/glia.22637 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|